IntrinsicIntrinsic
← All summaries

ENvue Medical, Inc.

FEED
Financials & Chart →

Business Summary

ENvue Medical, Inc. operates in the medical device industry, specifically within the enteral feeding and non-invasive ultrasound therapy markets. The global enteral feeding devices market size was valued at $4.62 billion in 2025, with an estimated compound annual growth rate of approximately 5.86% from 2024 to 2030, and a projected total market value of approximately $7.19 billion by 2030. The company's ENvue System addresses the approximately 43 million feeding tubes inserted annually worldwide, of which between 2-5% are placed in the lungs, leading to a 30% chance of a collapsed lung or possible fatality. The company also operates in the catheter-associated urinary tract infection (CAUTI) prevention market through its UroShield product, where the global urinary catheter market was valued at approximately USD 4.5–5.2 billion in 2023.

ENvue Medical faces competition from established medical device companies. For its ENvue System, primary competitors include Cardinal Health (with the IRIS Kangaroo Feeding Tube) and Avanos Medical (with the Cortrak 2 Enteral Access System). For its NanoVibronix business, competitors include Neurometrix Inc., Zetrox (a subsidiary of the 3M Company), and Smith & Nephew plc . The company's stated competitive advantages include its proprietary electromagnetic navigation technology, a portfolio of patents and trademarks, and a skilled workforce. The company believes the ENvue System is technologically distinct from the Cortrak device in several respects, including performing a registration to the patient's body that allows for the display of the patient-specific chest contour, providing a graphical and textual alert for feeding tube entry into the patient's airway, and using the patient's anatomical landmarks for the navigation process .

ENvue Medical generates revenue through two primary business segments. The ENvue Medical division sells the ENvue System, a navigation platform for enteral feeding tube placement, along with recurring sales of proprietary disposable enteral feeding tubes and accessories such as syringes. The NanoVibronix division generates revenue from the sale of reusable controller devices and disposable components for its PainShield and UroShield products. For the year ended December 31, 2025, the percentage of revenues attributable to products was: PainShield and monthly kits 73% and Envue system and tubes 27% . For the year ended December 31, 2024, the percentage was: PainShield and monthly kits 99% and UroShield 1% .

ENvue Medical's product portfolio is divided into two main segments. The ENvue Medical segment's core product is the FDA 510(k)-cleared ENvue System, which assists in the insertion of a feeding tube into the digestive system using electromagnetic navigation. The system includes a main unit, disposable ENvue Feeding Tubes in three diameters (8 Fr., 10 Fr., and 12 Fr.) , and sensors. The company also has the Nutriseal Nasogastric Aspiration Tube (NGAT), which is not currently being manufactured or marketed. New products in development include a navigation system for children and preterm infants, an imaging navigation system (ENvue Plus), a peripherally inserted central catheter (PICC) procedure application, ENfit compatible syringes, and a robotic arm platform (ENvue Drive). The NanoVibronix segment's primary products are PainShield, a patch-based therapeutic ultrasound device for pain, and UroShield, an ultrasound-based product for preventing biofilm in urinary catheters. PainShield MD is cleared for marketing in the United States by the FDA , and both PainShield and UroShield have CE Mark approval in the European Union .

During the fiscal year, ENvue Medical completed several significant operational developments. On February 14, 2025, the company consummated a merger with ENvue Medical Holdings Corp., issuing 3,318 shares of common stock, Pre-Funded Warrants to purchase up to 12,526 shares of common stock at an exercise price of $0.001 per share, and 57,720 shares of Series X Non-Voting Convertible Preferred Stock. The company also effected two reverse stock splits: a 1-for-11 reverse stock split effective March 13, 2025, and a 1-for-10 reverse stock split effective August 11, 2025. In May 2025, the company closed an underwritten public offering of 40,000 shares of Series G Convertible Preferred Stock and warrants, with aggregate net proceeds of approximately $8.2 million . In July 2025, the company entered into a securities purchase agreement for the sale of Series H Convertible Preferred Stock, with aggregate net proceeds of $9 million . In September 2025, the company completed a registered direct offering of common stock and pre-funded warrants for net proceeds of approximately $1.88 million . In January 2026, ENvue announced the launch of ENfit compatible syringes and signed a distribution agreement with U-Deliver .

For the fiscal year ended December 31, 2025, ENvue Medical reported total revenues of approximately $2,553 , a decrease of approximately $5 , or 0.2% , year over year from $2,558 in 2024. Gross profit was approximately $153 , a decrease of approximately 90% or $1,355 from $1,508 in 2024. The company reported a net loss of approximately $18,185 for 2025, compared to a net loss of approximately $3,705 in 2024, an increase of approximately $14,480 or 391% . As of December 31, 2025, the company had an accumulated deficit of approximately $90.5 million and a cash balance of $4.2 million .

Business Outlook

A primary growth vector for ENvue Medical is the continued commercialization of the ENvue System in the United States acute care hospital market. The company is focused on expanding its sales, marketing, and clinical education activities to drive adoption of the system and its associated disposable products across hospital intensive care units and other clinical settings. The company has established commercial engagements with multiple hospitals in the United States for evaluation and clinical use . Another growth vector is the expansion of the product portfolio to address additional clinical applications related to enteral access and other intrabody navigation procedures, including the development of the ENvue Drive robotic platform and the ENfit compatible syringes, which represent the company's first commercial step into non-acute care channels .

A second major growth vector is the international expansion of both the ENvue System and NanoVibronix products. For the ENvue System, the company may seek to expand commercialization activities into additional international markets, subject to obtaining applicable regulatory approvals and establishing appropriate distribution infrastructure . For NanoVibronix, a significant opportunity is the recent addition of the UroShield Kit to the UK National Health Service (NHS) Drug Tariff Part IX in November 2025 , enabling nationwide prescription reimbursement across the UK. The company is also seeking reimbursement codes for its products in other markets, including the United States . Additionally, the company is continuing to assess the route for FDA clearance/approval for UroShield in the United States .

The company's gross margin was significantly impacted in fiscal 2025, declining primarily due to the removal of PainShield Ultra from the market, inventory write-downs associated with PainShield Ultra, and amortization expense related to intangible assets recognized in connection with the ENvue merger, which is recorded within cost of goods sold . Gross profit as a percentage of revenues was approximately 6% for the year ended December 31, 2025, compared to 59% in 2024. The company expects to continue to incur losses and negative cash flows from operations .

ENvue Medical does not manufacture the products it sells for its ENvue division, instead contracting with suppliers for raw materials, components, and assembly . The company estimates that there may be a limitation on the potential annual production capacity at the supplier that assembles the ENvue System, but believes it could contract with an additional manufacturer if necessary, potentially replacing or expanding existing assembly capabilities within 6-9 months without significant cost changes. For NanoVibronix products, all programming and disposable kit manufacturing are performed in the company's facilities in Israel, with a plan to move manufacturing to a Contract Manufacturer located in the US . As of December 31, 2025, ENvue had 12 full-time employees and 2 part-time employees .

The company's capital allocation strategy is focused on funding operations through a combination of equity financings and potential strategic alliances. During fiscal 2025, the company raised significant capital through multiple transactions. The May 2025 underwritten public offering of Series G Preferred Stock generated aggregate net proceeds of approximately $8.2 million . The July 2025 private placement of Series H Preferred Stock generated aggregate net proceeds of $9 million . The September 2025 registered direct offering generated net proceeds of approximately $1.88 million . The company also issued a promissory note in April 2025 for a principal amount of $360 , which was subsequently paid in full in May 2025 . Research and development expenses for the year ended December 31, 2025, were approximately $1,762 , an increase of approximately $853 or 94% from $909 in 2024.

A significant headwind for ENvue Medical is its history of recurring losses and substantial doubt about its ability to continue as a going concern. For the fiscal year ended December 31, 2025, the company had a net loss of approximately $18.2 million and cash used in operations was $9.4 million , leaving a cash balance of $4.2 million as of December 31, 2025. Management has stated that the company does not have sufficient resources to fund its operations for the next twelve months from the date of the filing . Another major constraint is the company's operations in Israel, which expose it to political, economic, and military instability, including the ongoing conflict with Hamas and other regional hostilities that could disrupt operations, supply chains, and the ability to raise capital .

Additional headwinds include the company's need to maintain compliance with Nasdaq's continued listing requirements. The company has received deficiency notices regarding the minimum bid price and stockholders' equity requirements and has been granted a limited extension to demonstrate compliance, subject to a mandatory panel monitor for a period of one year . The company also faces risks related to its ability to obtain and maintain adequate levels of reimbursement for its products from third-party payers, which is critical for market acceptance. For PainShield, CMS denied reimbursement in September 2022 due to a lack of 'life-cycle' testing, and the company is currently evaluating whether to resubmit another application .

Risk Factors

ENvue Medical faces material risks, most critically its history of recurring losses and substantial doubt about its ability to continue as a going concern. For the fiscal year ended December 31, 2025, the company had a net loss of approximately $18.2 million and cash used in operations of $9.4 million , with an accumulated deficit of approximately $90.5 million and a cash balance of only $4.2 million as of December 31, 2025. Management has stated it does not have sufficient resources to fund operations for the next twelve months . The company is also exposed to significant operational risks from its activities in Israel, including the ongoing military conflict with Hamas and other regional hostilities, which could disrupt its supply chain, operations, and ability to raise capital . Furthermore, the company faces the risk of delisting from Nasdaq, having received deficiency notices for both the minimum bid price and stockholders' equity requirements, and is currently under a mandatory panel monitor for one year . The company also has a material legal risk from the Protrade arbitration, for which it has accrued approximately $2.3 million as of December 31, 2025.

Management Priorities

Management's message in the filing emphasizes the strategic transformation of the company following the merger with ENvue Medical Holdings Corp., which positions the combined entity to focus on the enteral feeding market with the ENvue System. The tone is forward-looking but acknowledges significant financial challenges, including a history of losses and substantial doubt about the company's ability to continue as a going concern. Key strategic priorities for the period ahead include: (1) driving the commercial adoption of the ENvue System in U.S. acute care hospitals by expanding sales, marketing, and clinical education activities; (2) broadening the product portfolio through new product development, including the ENvue Drive robotic platform and ENfit compatible syringes; and (3) seeking to expand commercialization into additional international markets and secure regulatory approvals and reimbursement for its products.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — ENvue Market Opportunity and Trends
  2. [2] Item 1, Business — ENvue Market Opportunity and Trends
  3. [3] Item 1, Business — ENvue Market Opportunity and Trends
  4. [4] Item 1, Business — ENvue's Business
  5. [5] Item 1, Business — ENvue's Business
  6. [6] Item 1, Business — ENvue's Business
  7. [7] Item 1, Business — Nano OpCo's Business, Competition for UroShield
  8. [8] Item 1, Business — Competition for ENvue System
  9. [9] Item 1, Business — Competition for ENvue System
  10. [10] Item 1A, Risk Factors — Risks Related to Our Business
  11. [11] Item 1, Business — Competition for ENvue System
  12. [12] Item 7, MD&A — Results of Operations
  13. [13] Item 7, MD&A — Results of Operations
  14. [14] Item 7, MD&A — Results of Operations
  15. [15] Item 7, MD&A — Results of Operations
  16. [16] Item 1, Business — ENvue Products, The ENvue System
  17. [17] Item 1, Business — Nano OpCo's Business
  18. [18] Item 1, Business — Nano OpCo's Business
  19. [19] Item 1, Business — The Merger Agreement
  20. [20] Item 1, Business — The Merger Agreement
  21. [21] Item 1, Business — The Merger Agreement
  22. [22] Item 1, Business — The Merger Agreement
  23. [23] Item 1, Business — 2025 Reverse Stock Splits
  24. [24] Item 1, Business — 2025 Reverse Stock Splits
  25. [25] Item 7, MD&A — May 2025 Underwritten Public Offering
  26. [26] Item 7, MD&A — May 2025 Underwritten Public Offering
  27. [27] Item 7, MD&A — July 2025 Private Placement of Series H Preferred Stock
  28. [28] Item 7, MD&A — September 2025 Registered Direct Offering
  29. [29] Item 1, Business — ENvue Products, ENfit Compatible Syringes
  30. [30] Item 7, MD&A — Results of Operations
  31. [31] Item 7, MD&A — Results of Operations
  32. [32] Item 7, MD&A — Results of Operations
  33. [33] Item 7, MD&A — Results of Operations
  34. [34] Item 7, MD&A — Results of Operations
  35. [35] Item 7, MD&A — Results of Operations
  36. [36] Item 7, MD&A — Results of Operations
  37. [37] Item 7, MD&A — Results of Operations
  38. [38] Item 7, MD&A — Results of Operations
  39. [39] Item 7, MD&A — Results of Operations
  40. [40] Item 7, MD&A — Results of Operations
  41. [41] Item 7, MD&A — Results of Operations
  42. [42] Item 1A, Risk Factors — Risks Related to Our Business
  43. [43] Item 1A, Risk Factors — Risks Related to Our Business
  44. [44] Item 1, Business — ENvue Strategy
  45. [45] Item 1, Business — ENvue Products, ENfit Compatible Syringes
  46. [46] Item 1, Business — ENvue Strategy
  47. [47] Item 1, Business — Nano OpCo's Business, UroShield
  48. [48] Item 1, Business — Nano OpCo's Business, Insurance Coverage and Reimbursement
  49. [49] Item 1, Business — Nano OpCo's Business, Regulatory Strategy
  50. [50] Item 7, MD&A — Results of Operations
  51. [51] Item 7, MD&A — Results of Operations
  52. [52] Item 7, MD&A — Results of Operations
  53. [53] Item 7, MD&A — Liquidity and Capital Resources
  54. [54] Item 1, Business — Manufacturing and Suppliers
  55. [55] Item 1, Business — Manufacturing and Suppliers
  56. [56] Item 1, Business — Nano OpCo's Products, Product Design, Packaging, Identity
  57. [57] Item 1, Business — Our People and Human Capital Resources
  58. [58] Item 7, MD&A — May 2025 Underwritten Public Offering
  59. [59] Item 7, MD&A — July 2025 Private Placement of Series H Preferred Stock
  60. [60] Item 7, MD&A — September 2025 Registered Direct Offering
  61. [61] Item 7, MD&A — April 2025 Promissory Note and Guaranty
  62. [62] Item 7, MD&A — April 2025 Promissory Note and Guaranty
  63. [63] Item 7, MD&A — Results of Operations
  64. [64] Item 7, MD&A — Results of Operations
  65. [65] Item 7, MD&A — Results of Operations
  66. [66] Item 7, MD&A — Results of Operations
  67. [67] Item 1A, Risk Factors — Risks Related to Our Business
  68. [68] Item 1A, Risk Factors — Risks Related to Our Business
  69. [69] Item 1A, Risk Factors — Risks Related to Our Business
  70. [70] Item 1A, Risk Factors — Risks Related to Our Business
  71. [71] Item 1A, Risk Factors — Risks Related to Our Operations in Israel
  72. [72] Item 7, MD&A — Nasdaq Minimum Stockholder's Bid Price Requirement
  73. [73] Item 1, Business — Nano OpCo's Business, PainShield Sales and Marketing
  74. [74] Item 1A, Risk Factors — Risks Related to Our Business
  75. [75] Item 1A, Risk Factors — Risks Related to Our Business
  76. [76] Item 1A, Risk Factors — Risks Related to Our Business
  77. [77] Item 1A, Risk Factors — Risks Related to Our Business
  78. [78] Item 1A, Risk Factors — Risks Related to Our Business
  79. [79] Item 1A, Risk Factors — Risks Related to Our Operations in Israel
  80. [80] Item 7, MD&A — Nasdaq Minimum Stockholder's Bid Price Requirement
  81. [81] Item 3, Legal Proceedings — Protrade Proceeding
  82. [82] Item 8, FS — Consolidated Statements of Operations
  83. [83] Item 8, FS — Consolidated Statements of Operations
  84. [84] Item 8, FS — Consolidated Statements of Operations
  85. [85] Item 8, FS — Consolidated Statements of Operations
  86. [86] Item 8, FS — Consolidated Statements of Operations
  87. [87] Item 8, FS — Consolidated Statements of Operations
  88. [88] Item 8, FS — Consolidated Statements of Operations
  89. [89] Item 8, FS — Consolidated Statements of Operations
  90. [90] Item 8, FS — Consolidated Statements of Operations
  91. [91] Item 8, FS — Consolidated Statements of Operations
  92. [92] Item 7, MD&A — Results of Operations
  93. [93] Item 7, MD&A — Results of Operations
  94. [94] Item 7, MD&A — Results of Operations
  95. [95] Item 8, FS — Consolidated Statements of Operations
  96. [96] Item 8, FS — Consolidated Statements of Operations
  97. [97] Item 7, MD&A — Results of Operations
  98. [98] Item 7, MD&A — Results of Operations
  99. [99] Item 7, MD&A — Results of Operations
  100. [100] Item 8, FS — Consolidated Balance Sheets
  101. [101] Item 8, FS — Consolidated Balance Sheets
  102. [102] Item 8, FS — Consolidated Balance Sheets
  103. [103] Item 8, FS — Consolidated Balance Sheets
  104. [104] Item 8, FS — Consolidated Balance Sheets
  105. [105] Item 8, FS — Consolidated Balance Sheets

Analysis on 6/22/2026